This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vincent-Salomon, A. Articles by Heard, E. Search for Related Content PubMed PubMed Citation Articles by Vincent-Salomon, A. Articles by Heard, E.

X Inactive–Specific Transcript RNA Coating and Genetic Instability of the X Chromosome in BRCA1 Breast Tumors

¹ Institut Curie, Centre de Recherche; ² Centre National de la Recherche Scientifique Unité Mixte de Recherche 218, Institut Curie; ³ Institut National de la Santé et de la Recherche Médicale U830; and ⁴ Department of Tumor Biology, Institut Curie, Paris, France

Requests for reprints: Edith Heard, Centre National de la Recherche Scientifique Unité Mixte de Recherche 218, Institut Curie, Centre de Recherche, 26 rue d'Ulm, Paris F-75248, France. Phone: 33-1-42-34-66-91; Fax: 33-1-46-33-30-16; E-mail: edith.heard{at}curie.fr or Marc-Henri Stern, Institut National de la Santé et de la Recherche Médicale U830 Institut Curie, Centre de Recherche, 26 rue d'Ulm, Paris F-75248, France. Phone: 33-1-42-34-66-46; Fax: 33-1-42-34-66-30; E-mail: marc-henri.stern{at}curie.fr.

Identification among breast tumors of those arising in a hereditary BRCA1 context remains a medical challenge. Abnormalities in X chromosome copy number and in the epigenetic stability of the inactive X chromosome (Xi) have been proposed to characterize BRCA1 breast tumors. In particular, it has been proposed that loss of BRCA1 function can lead to loss of X inactive–specific transcript (XIST) RNA association with the Xi. However, few studies have addressed this issue in a sufficiently large series of BRCA1 primary tumors. Here we assess X-chromosome status using single-cell (RNA and DNA fluorescence in situ hybridization) and global genomic (array-comparative genomic hybridization and allelotyping) approaches on a series of 11 well-defined BRCA1 tumors. We show that many or most cells of the tumors contain one or more XIST RNA domains. Furthermore, the number of XIST RNA domains per cell varied considerably even within a single tumor. Frequent X-chromosome allelic and copy number aberrations were found, in agreement with aberrant XIST RNA domain numbers. In summary, by combining multiple approaches to assess the genetics and epigenetics of a large series of BRCA1 primary tumors, we can conclude definitively that BRCA1 is not required for XIST RNA coating of the X chromosome. The intratumoral and intertumoral variability in XIST RNA domain number in BRCA1 tumors correlates with chromosomal genetic abnormalities, including gains, losses, reduplications, and rearrangements of the X-chromosome. Finally, we also show the necessity for combined global and single-cell approaches in the assessment of tumors with such a high degree of heterogeneity. [Cancer Res 2007;67(11):5134–40]

This article has been cited by other articles:

				F. Lose, D. L. Duffy, G. F. Kay, Kathleen Cuningham Foundation Consortium for Resea, M. A. Kedda, and A. B. Spurdle Skewed X Chromosome Inactivation and Breast and Ovarian Cancer Status: Evidence for X-Linked Modifiers of BRCA1 J Natl Cancer Inst, November 5, 2008; 100(21): 1519 - 1529. [Abstract] [Full Text] [PDF]

				I. O-Sullivan, A. Chopra, J. Carr, T. S. Kim, and E. P. Cohen Immunity to Growth Factor Receptor-Bound Protein 10, a Signal Transduction Molecule, Inhibits the Growth of Breast Cancer in Mice Cancer Res., April 1, 2008; 68(7): 2463 - 2470. [Abstract] [Full Text] [PDF]